#1
Sunesis Pharmaceuticals,
Abro este post para los que tengamos acciones de Sunesis Pharmaceuticals,
#2
Re: Sunesis Pharmaceuticals,
Apuntame, je,je,
Tiene conferncia en ASCO con su producto Vosaroxin el dia 4 de Junio.Y en la FDA su calendario es el dia 30/9/2012 del mismo producto en combinación con citarabina.
Suerte y salud
#3
Re: Sunesis Pharmaceuticals,
#4
Re: Sunesis Pharmaceuticals,
SNSS
Exelixis reported additional positive data from a Phase III pivotal trial evaluating cabozantinib in the treatment of progressive, unresectable, and locally advanced or metastatic medullary thyroid cancer (MTC). The firm completed its cabozantinib NDA submission to FDA for the MTC indication at the end of May.
Carried out under Special Protocol Assessment with FDA, the placebo-controlled Exam study involved 330 patients. The study met its primary endpoint in terms of increasing median progression free survival (PFS) from 4 months (for placebo-treated patients) to 11.2 months for patients in the capozantinib arm. Cabozantinib therapy was associated with an estimated PFS at one year of 47.3%, compared with 7.2% for placebo. The overall response rate was 28% for cabozantinib-treated patients, and 0% among placebo-treated patients. Data for overall survival isn’t yet mature, Exelixis reports.
Cabozantinib is a targeted therapy that inhibits MET, VEGFR2, and RET, and has demonstrated tumoricidal, antimetastatic, and antiangiogenic effects. “Beyond MTC, we are also excited about the encouraging interim cabozantinib data that has been generated in a variety of other tumor indications, including hepatocellular carcinoma, renal cell carcinoma, and castration-resistant prostate cancer,” comments Michael M. Morrissee, Ph.D., president and CEO at Exelixis. “In particular, the prostate cancer data formed the basis for advancing cabozantinib into two recently initiated Phase III pivotal trials, Comet-1 and Comet-2."
EditO
http://www.genengnews.com/gen-news-highlights/phase-iii-study-shows-exelixis-cabozantinib-triples-pfs-in-metastatic-medullary-thyroid-cancer/81246851/#utm_medium=twitter%26utm_medium=social%26utm_campaign=june
#5
Re: Sunesis Pharmaceuticals,
SNSS
http://www.biomedreports.com/2012060796532/sunesis-has-been-enjoying-a-rally-thus-far-in-2012.html
Nos tenemos que esperar al Tercer trimestre de 2012 para ver si le aprueban el medicamento.
#6
Re: Sunesis Pharmaceuticals
Yo ayer le meti venta limitada a SNSS y me quede super agusto con unos pocos profits, muy poquitos, pero contento de salirme.
Y hoy, segun me levanto y compruebo cartera me doy cuenta que solo me vendió como que la mitad de las acciones mas o menos.
Y ahora ya estoy pillado salvo que mañana rebote.
Ain ....
#7
Re: Sunesis Pharmaceuticals
Framus entonces NO le ves recorrido.???
Pero lo bueno es que todo son buenas noticias,,,,,,
Me cagón en........
#8
Re: Sunesis Pharmaceuticals,
La veo fuerte potencial por encima de 3.30.
Objetivo: 4.73 - 5.41 - 5.56
Stop: 2.48
Quizas algo alejado el stop, luego se podría ajustar más...... pero me ha gustado su potencial y el HCH invertido que tiene.
No voy a comprar........ asi que buena suerte a los que entreís.
Saludos
